Back to Search
Start Over
Anti-myeloma activity of MELK inhibitor OTS167: effects on drug-resistant myeloma cells and putative myeloma stem cell replenishment of malignant plasma cells.
- Source :
-
Blood cancer journal [Blood Cancer J] 2016 Aug 19; Vol. 6 (8), pp. e460. Date of Electronic Publication: 2016 Aug 19. - Publication Year :
- 2016
-
Abstract
- Competing Interests: YN is a stock holder and a scientific advisor of OncoTherapy Science, Inc. JP is a scientific advisor of OncoTherapy Science, Inc. YM and SC are employees of OncoTherapy Science, Inc. AJJ is a consultant, member of the advisory board and receives honoraria from Bristol-Myers Squibb, Celgene, Janssen Pharmaceuticals, Karyopharm Therapeutics, Millennium/Takeda Pharmaceuticals, Onyx/Amgen Pharmaceuticals, Sanofi-Aventis and SkylineDx. The remaining authors declare no conflict of interest.
- Subjects :
- Antineoplastic Agents therapeutic use
Bone Marrow Cells drug effects
Bone Marrow Cells pathology
Cells, Cultured
Dose-Response Relationship, Drug
Drug Screening Assays, Antitumor
Humans
Multiple Myeloma drug therapy
Naphthyridines therapeutic use
Neoplastic Stem Cells pathology
Plasma Cells pathology
Protein Kinase Inhibitors therapeutic use
Tumor Microenvironment drug effects
Antineoplastic Agents pharmacology
Drug Resistance, Neoplasm drug effects
Multiple Myeloma pathology
Naphthyridines pharmacology
Neoplastic Stem Cells drug effects
Plasma Cells drug effects
Protein Kinase Inhibitors pharmacology
Protein Serine-Threonine Kinases antagonists & inhibitors
Subjects
Details
- Language :
- English
- ISSN :
- 2044-5385
- Volume :
- 6
- Issue :
- 8
- Database :
- MEDLINE
- Journal :
- Blood cancer journal
- Publication Type :
- Academic Journal
- Accession number :
- 27540718
- Full Text :
- https://doi.org/10.1038/bcj.2016.71